BioWorld

June 1, 2006

View Archived Issues

As First Step In Biogeneric Debate, Omnitrope Cleared

The FDA approved the biosimilar product Omnitrope (somatropin [rDNA origin]), a follow-on version of a growth hormone drug, in a landmark decision that reverberated among both supporters and opponents. (BioWorld Today) Read More

FDA Refuses NDA Filing For RSD1235; Cardiome Plunges

Read More

Cell Growth Kinase Integrates Circulating, Stored Fuel Signal

Read More

Biogen Buying Fumapharm, Consolidating BG-12 Rights

Read More

Isis Gains Flexibility Via $75M Equity Financing Commitment

Read More

Clinic Roundup

Read More

Other News To Note

Read More